tiprankstipranks
Advertisement
Advertisement

SVRA Stock Latest News

Savara says FDA extended review for Molgramostim BLA
The FlySavara says FDA extended review for Molgramostim BLA
8d ago
SVRA
Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP
PremiumRatings
Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP
17d ago
SVRA
Savara announces MHRA accepted submission of Molbreevi MAA
PremiumThe Fly
Savara announces MHRA accepted submission of Molbreevi MAA
17d ago
SVRA
Savara announces EMA validation of MAA for MOLBREEVI
PremiumThe Fly
Savara announces EMA validation of MAA for MOLBREEVI
25d ago
SVRA
De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi
PremiumRatings
De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi
1M ago
SVRA
Savara: Regulatory Momentum and Strong Phase 3 Data Underpin Buy Rating and $11 Upside Target
PremiumRatingsSavara: Regulatory Momentum and Strong Phase 3 Data Underpin Buy Rating and $11 Upside Target
1M ago
SVRA
Midday Fly By: Adobe CEO to step down, Meta delays ‘Avocado’ AI model launch
Premium
The Fly
Midday Fly By: Adobe CEO to step down, Meta delays ‘Avocado’ AI model launch
1M ago
BX
MS
Savara Signs Long-Term Lease for New Headquarters
Premium
Company Announcements
Savara Signs Long-Term Lease for New Headquarters
1M ago
8K
SVRA
Savara reports Q4 EPS (13c), consensus (12c)
PremiumThe Fly
Savara reports Q4 EPS (13c), consensus (12c)
1M ago
SVRA
Savara announces receipt of Day 74 Letter from FDA
PremiumThe Fly
Savara announces receipt of Day 74 Letter from FDA
2M ago
SVRA
Savara says FDA files BLA for Molbreevi
PremiumThe Fly
Savara says FDA files BLA for Molbreevi
2M ago
SVRA
Savara announces BLA for Molbreevi filed for review by FDA
PremiumThe Fly
Savara announces BLA for Molbreevi filed for review by FDA
2M ago
SVRA
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach
PremiumCompany AnnouncementsSavara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach
2M ago
SVRA
Savara Enters New Material Definitive Agreement and Obligation
Premium
Company Announcements
Savara Enters New Material Definitive Agreement and Obligation
3M ago
8K
SVRA
Savara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential
Premium
Ratings
Savara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential
3M ago
SVRA
Savara Highlights Autoimmune PAP Burden in Updated Presentation
PremiumCompany Announcements
Savara Highlights Autoimmune PAP Burden in Updated Presentation
3M ago
8K
SVRA
Savara (SVRA): Molbreevi De-Risking and Enhanced aPAP Market Visibility Support Higher Target and Buy Rating
PremiumRatings
Savara (SVRA): Molbreevi De-Risking and Enhanced aPAP Market Visibility Support Higher Target and Buy Rating
4M ago
SVRA
Savara price target raised to $10 from $8 at H.C. Wainwright
PremiumThe Fly
Savara price target raised to $10 from $8 at H.C. Wainwright
4M ago
SVRA
Savara (SVRA): Buy Rating on High MOLBREEVI Approval Odds and Blockbuster Commercial Potential
PremiumRatings
Savara (SVRA): Buy Rating on High MOLBREEVI Approval Odds and Blockbuster Commercial Potential
4M ago
SVRA
Savara resubmits Molbreevi BLA to the FDA
PremiumThe FlySavara resubmits Molbreevi BLA to the FDA
4M ago
SVRA
Savara announces EPO intention to grant Molbreevi patent application
Premium
The Fly
Savara announces EPO intention to grant Molbreevi patent application
4M ago
SVRA
Savara’s MOLBREEVI: A Promising Solution for aPAP with Blockbuster Potential
Premium
Ratings
Savara’s MOLBREEVI: A Promising Solution for aPAP with Blockbuster Potential
4M ago
SVRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >